Company Overview/History

PRINT

Basic Information

(As of April 1, 2024)

Company name ASKA Pharmaceutical Co., Ltd.
Address
5-1, Shibaura 2-Chome, Minato-ku, Tokyo
108-8532, Japan
Tel: +81-3-5484-8361
Founded June 16, 1920
Established June 28, 1929
Business segments Manufacturing, sale and import/export of pharmaceuticals, veterinary medicines, quasi-drugs, foods, and medical devices, etc.
Representative Sohta Yamaguchi
President, Representative Director
Executives Please see the list of Executives.
Business locations Please see the list of Offices and Group Companies for locations.
Group companies Please see the list of Offices and Group Companies for information on group companies.
Capital ¥1,197.9 million
Number of employees 642 (112)*
Main Bank MUFG Bank, Ltd.
URL https://www.aska-pharma.co.jp/english/
  • *Number of employees is the number of full-time employees who actually work as of March 31, 2024. Figures in parentheses represent the average number of temporary employees during the year and are not included in the number of full-time employees.

Organization Chart

(As of April 1, 2024)

History

June
1920
Established Teikoku Hormone Research Institute by Founder Yasohachi Yamaguchi
June
1921
Launched SPERMATIN, a male gonadal hormone agent
July
1922
Launched THYRADIN, a Hypothyroidism agent
June
1929
Reorganized as a corporation, Teikoku Hormone Mfg. Research Laboratory Co., Ltd.
January
1936
Constructed Takatsu Factory (Kawasaki Research Center) in Kawasaki-shi (former Tachibana-gun), Kanagawa
October
1945
Changed company name to Teikoku Hormone Mfg. Co., Ltd.
October
1946
Moved head office to Nishi-Shinbashi, Minato-ku, Tokyo (formerly Shiba-Minamisakuma-cho, Shiba-ku, Tokyo)
January
1952
Appointed Eiichi Yamaguchi as President
September
1955
Listed on the Tokyo Stock Exchange
June
1957
Began veterinary medicine production and sales
November
1962
Moved Head Office to Akasaka, Minato-ku
August
1971
Started clinical testing business
July
1975
Started medical equipment business
April
1980
Constructed Iwaki Factory in Fukushima
September
1981
Launched PROSTAL TABLETS, a benign prostatic hyperplasia treatment (Indication for prostate cancer added in May 1983)
October
1986
Launched ALTAT CAPSULES, a gastritis agent (Indication for gastric ulcer added in June 1993)
May
1991
Established Medical System Service Kanagawa, Inc. (now ASKA Pharma Medical Co., Ltd.)
June
1991
Appointed Takashi Yamaguchi as President
April
1997
Established International Representative Office in Frankfurt, Germany
September
1999
Launched ANGE , an oral contraceptive
June
2000
80th anniversary
September
2001
Constructed and moved Head Office building in Shibaura, Minato-ku
March
2005
Launched LIPIDIL capsules, a hyperlipidemic agent
October
2005
Merged with Teikoku Hormone and Grelan, changed company name as ASKA Pharmaceutical Co., Ltd.
May
2011
Launched NORLEVO TABLET, an emergency contraceptive
December
2011
Launched LIPIDIL TABLETS, a hyperlipidemic agent
April
2013
Completed the Quality Control Building in Iwaki Factory
June
2013
Established ASKA Animal Health Co., Ltd. as a subsidiary
February
2014
Launched LEUPRORELIN ACETATE FOR INJECTION KIT “ASKA”, an Endometriosis, uterine fibroids, and prostate cancer agent
September
2014
Launched CANDESARTAN TABLETS “ASKA”, an antihypertensive agent
October
2015
10th Anniversary of ASKA Pharmaceutical. Co., Ltd.
October
2015
Transferred manufacturing and marketing rights, and marketing approval of the antithyroid agents MERCAZOLE TABLETS, MERCAZOLE Injection, and PROPACIL TABLETS from Chugai Pharmaceutical Co., Ltd.
February
2016
Completed the Fourth Pharmaceutical Manufacturing Building in Iwaki Factory
April
2016
Launched LUTEUM VAGINAL SUPPOSITORIES, infertility agent
November
2016
Launched RIFXIMA TABLETS, a hepatic encephalopathy agent
October
2018
Jointly with Omnicare Drugs India Private Limited, invested in NeoASKApharma Private Limited in India.
December
2018
Launched FREWELL Combination Tablets LD “ASKA”, Combination Tablets ULD “ASKA”, a dysmenorrhea agent
March
2019
Launched RELUMINA tablets, uterine fibroids agent (Indication for endometriosis added in December 2021)
February
2020
Transferred rights related to manufacturing and marketing approval for “Magsent Injection”, “Magsent Injection Syringe”, indicated for preventing uterine contraction, and “IV MAGNESOL” which is indicated for the prevention and treatment of eclampsia from TOA Biopharma Co., Ltd
April
2020
Relocated Kawasaki Research Center to Shonan Health Innovation Park
Initiated as Shonan Research Center
June
2020
100th anniversary
June
2020
Established Mint Health Lab for Women’s health
June
2020
Launched THYRADIN-S Injection, a Hypothyroidism
January
2021
Vietnamese company, Ha Tay Pharmaceutical Joint Stock Company became an equity method affiliated company
April
2021
Established ASKA Pharmaceutical Holdings Co., Ltd.
April
2021
Established the London Office in England as our international representative office
June
2021
Appointed Sohta Yamaguchi as President
June
2022
Launched DroEthi Combination Tablet “ASKA”, a dysmenorrhea agent
TOP